ABSTRACT OBJECTIVES This study sought to assess the prevalence and clinical impact of silent diabetes and pre-diabetes in "nondiabetic" percutaneous coronary intervention (PCI) all-comers.
D iabetes mellitus (DM) is associated with
adverse outcome in the general population and even more so in patients with cardiovascular disease (1) . Many patients with coronary artery disease share risk factors with the metabolic syndrome and are for that reason at risk of developing diabetes (2) . Diabetic patients, who represent an increasing proportion of all patients referred for percutaneous coronary intervention (PCI), are at a higher adverse events risk (3, 4) and continue to show a higher mortality despite the development of newer-generation drug-eluting stents (DES) with improved biocompatibility (4) (5) (6) (7) . Traditionally, the diagnosis of diabetes or pre-diabetes (impaired glucose tolerance [IGT] and impaired fasting glucose [IFG] )-an early stage of diabetes-is made based on increased fasting plasma glucose (FPG) levels or oral glucose tolerance testing (OGTT) or elevated glycosylated hemoglobin (HbA 1c ) (8) (9) (10) .
A substantial proportion of patients have undetected and thus untreated (silent) diabetes, which may lead to more cardiovascular complications.
Abnormal glucose metabolism with its chronic hyperglycemic state leads to dyslipidemia, hypercoagulability, increased atheroma burden, vessel wall inflammation, and vulnerable plaques (7, 11) . Previous post hoc analyses of data from the TWENTE (The Real-World Endeavor Resolute versus Xience V DrugEluting Stent Study in Twente) trial, which assessed PCI with newer-generation DES in a broad patient population (12), suggested a relation between undetected diabetes and outcome following PCI (13) . In addition, based on data from the EUROASPIRE IV (European Action on Secondary and Primary Prevention by Intervention to Reduce Events) study (14) , it was recently recommended that all patients with cardiovascular disease should undergo OGTT, which is considered by some, but not all (15) , a standard for detecting diabetes (8, 9, 14, 16) . Ingelheim, Novo Nordisk, Eli Lilly and Co., and Janssen; has received research grant support from Boehringer Ingelheim and AstraZeneca; and has received personal fees from AstraZeneca. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose. Drs. von Birgelen and Kok contributed equally to this work.
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Helsinki and was approved by the Medical Ethics
Committee Twente (17) . All patients provided written informed consent. (17) . In general, dual antiplatelet therapy was prescribed for 6 to 12 months.
Electrocardiograms were systematically assessed. von Birgelen et al. Baseline characteristics and procedural details of patients with silent diabetes, pre-diabetes, and normal glucose metabolism are presented in Table 2 .
Patients with abnormal glucose metabolism had a slightly higher body mass index, more often a previous myocardial infarction, and tended to be older than patients with normal glucose metabolism. Of the study participants, one-third had an abnormal glucose metabolism, of which 7% had silent diabetes mellitus (DM). At 1-year follow-up, more than one-half of the target vessel failures (TVFs) occurred in patients with abnormal glucose metabolism. Specifically, the 7% silent DM patients accounted for almost a one-quarter of all adverse events. PCI ¼ percutaneous coronary intervention.
The rate of the primary endpoint was significantly higher in patients with silent diabetes as compared with patients with pre-diabetes and normal glucose metabolism, based on OGTT (13.2% vs. 7.6% vs. 4.8%; p < 0.001). Primary endpoint rates in metabolic state groups, based on the HbA 1c and FPG levels, were similar to rates in OGTT-based analyses (12.1% vs. Table 3 ).
The incidence of target vessel MI was higher in patients with silent diabetes than in patients with von Birgelen et al. (17) . Significantly, the study was performed in a predominantly white European population in the Netherlands-a country that has a lower prevalence of diabetes than the United States and many other European countries (22) , and a health system that is characterized by a fine-meshed net of primary care that offers screening for several common diseases, including diabetes. Therefore, it is fair to assume that the proportion of silent diabetics among PCI patients may be higher than 7%, both in countries with a higher diabetes risk or more difficult access to primary care. from the United States in patients with ST-segment elevation MI identified silent diabetes in 9.2%; both in-hospital and 3-year mortality of patients with silent diabetes were found to be significantly increased (25) . A study in 500 elective PCI patients with HbA 1c levels <7.0% showed that an HbA 1c between 6% and 7% independently predicted cardiovascular events (26) . Another study from the United States identified 14% patients with silent diabetes based on abnormal FPG levels among PCI patients with acute coronary syndromes and showed silent diabetes to independently predict mortality (27) . A rate of 18% silent di- IMPLICATIONS. Our findings suggest that screening for abnormal glucose metabolism may be advisable, as it was associated with an increased adverse event Abbreviations as in Tables 1-4 . 
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